BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 28, 2010
View Archived Issues
CD56(bright) NK cell count predicts response to daclizumab in relapsing-remitting MS
Read More
Second dose enhances immunogenicity of MenACWY-TT flu vaccine in toddlers
Read More
Recent preclinical studies offer insight into mechanism of action of laquinimod
Read More
New clinical data presented on anticancer agents GSK-2118436 and GSK-1120212
Read More
Intravenous zanamivir administration is feasible in patients with severe flu
Read More
Takeda Pharma claims novel renin inhibitors
Read More
BMPR-1A inhibition by RAP-661 increases bone mass and strength in mice
Read More
Treakisym approved in Japan for non-Hodgkin's and mantle cell lymphoma
Read More
Evotec and Apeiron Biologics collaborate on DREAM modulators for pain
Read More
Shionogi obtains approval for pediatric use of peramivir in Japan
Read More
PTC Therapeutics begins phase II ataluren trial in nmMMA
Read More
MacroGenics and Pfizer enter into DART collaboration and license agreement
Read More
Achillion Pharmaceuticals patents novel antibacterial agents
Read More
Initial phase II results of resminostat in Hodgkin's lymphoma demonstrate favorable safety
Read More
New GSK-3 beta inhibitors claimed
Read More
Keryx completes enrollment in short-term phase III efficacy study of Zerenex
Read More
Cephalon gains TNF inhibitor assets with exercise of option to acquire BioAssets Development
Read More
Astellas Pharma's Vesicare OD approved in Japan for overactive bladder
Read More
New blockers of voltage-gated Ca(V)2.2 calcium channel described
Read More
Purdue Pharma and Mundipharma to develop Infinity Pharma's FAAH program
Read More
EpiCept to conduct phase III trial of Ceplene under FDA SPA
Read More
Pradax approved in Canada for stroke prevention in AF
Read More
Celator Pharma completes enrollment in phase II CPX-351 trial in AML
Read More
Nascobal to be commercialized outside U.S. for vitamin B12 deficiency
Read More
Pfizer obtains new indication approval for Lyrica in Japan
Read More
